Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER) (PIONEER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01938547
Recruitment Status : Suspended
First Posted : September 10, 2013
Last Update Posted : May 15, 2017
Sponsor:
Information provided by (Responsible Party):
Chiesi Farmaceutici S.p.A.

Brief Summary:
To evaluate the efficacy, safety and dosing of an intravenous (IV) infusion of clevidipine for blood pressure (BP) management in pediatric participants in the perioperative setting.

Condition or disease Intervention/treatment Phase
Pediatric Perioperative Blood Pressure Management Drug: clevidipine Phase 4

Detailed Description:
This is an open label study to assess, in a stepwise approach across 4 age cohorts from oldest to youngest (birth to <age 18), the efficacy and safety of clevidipine exposure for a minimum of 30 minutes and up to a maximum of 96 hours in pediatric participants undergoing a surgical procedure with anesthesia for greater than or equal to 1 hour and for whom parenteral intravenous antihypertensive therapy for the management of blood pressure is expected.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label Study to Assess the Efficacy, Safety and Dosing of Clevidipine in Pediatric Patients Undergoing Surgery
Actual Study Start Date : March 2014
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Clevidipine

Arm Intervention/treatment
Experimental: clevidipine

An initial clevidipine IV infusion dose for the adolescent cohort has been specified per protocol. The initial dose for each of the subsequent age cohorts will be modified if necessary, based on the recommendation of the Data and Safety Monitoring Board (DSMB).

Following the initial dose, clevidipine will be up-titrated every 1.5 minutes, according to participant need, to achieve a systolic blood pressure (SBP) within the pre-specified SBP target range. Doses may be increased by less than doubling, and the time between dose adjustments may be lengthened, as the target blood pressure is approached. The infusion rate may be maintained for up to 96 hours, once the participant's SBP is within the target range, and titrated as necessary to maintain blood pressure within the range.

Drug: clevidipine
Other Names:
  • Cleviprex
  • clevidipine butyrate




Primary Outcome Measures :
  1. Efficacy: Median time to attain the initial pre-specified target SBP range (≥20 mm Hg and ≤ 40 mm Hg apart) [ Time Frame: During the first 30 minutes of clevidipine infusion ]
  2. Efficacy: Dose to attain the initial pre-specified target SBP range (≥20 mm Hg and ≤ 40 mm Hg apart) [ Time Frame: During the first 30 minutes of clevidipine infusion ]
  3. Efficacy: Percentage of participants achieving the initial pre-specified target SBP range [ Time Frame: During the first 30 minutes of clevidipine infusion ]
  4. Pharmacology: Pharmacokinetic variables [half-life, Area Under the Curve (AUC), volume of distribution, clearance] established by noncompartmental analysis or sparse population methodology [ Time Frame: Through 8 hours post-termination of clevidipine infusion (minimum of 9 hours up to a maximum of approximately 4 1/2 days) ]
  5. Pharmacology: Pharmacodynamic variables (relationship between change from baseline in SBP versus blood concentration and infusion rate) [ Time Frame: Duration of clevidipine infusion (minimum of 30 minutes up to a maximum 96 hours) ]
  6. Safety: Safety of a prolonged infusion of clevidipine assessed through clinical laboratory parameters, adverse events and serious adverse events (SAEs) [ Time Frame: Through 7 days post-termination of clevidipine infusion (minimum of approximately 7 1/2 days up to a maximum of approximately 11 1/2 days) ]

Secondary Outcome Measures :
  1. Efficacy: The percentage of participants who reach the initial pre-specified target SBP range without falling below the lower limit of the pre-specified target range [ Time Frame: During the first 30 minutes of clevidipine infusion ]
  2. Efficacy: The percentage of participants in whom the SBP falls below the lower limit of the pre-specified target range at any time [ Time Frame: During the first 30 minutes of clevidipine infusion ]
  3. Efficacy: The percentage of participants in whom the SBP falls below the lower limit of the pre-specified target range at any time during the entire study drug treatment period [ Time Frame: Minimum of 30 minutes up to a maximum of 96 hours ]
  4. Efficacy: The percentage of participants in whom the SBP is within target range at each hour after the first 30 minutes of clevidipine infusion [ Time Frame: 30 minutes post-clevidipine infusion through termination of clevidipine infusion (minimum of <1 minute up to a maximum of 95 1/2 hours) ]
  5. Efficacy: The percentage of participants who require rescue therapy (i.e. receive any alternative IV antihypertensive drug) at any time during the study drug treatment period [ Time Frame: Minimum of 30 minutes up to a maximum of 96 hours ]
  6. Efficacy: Percent change in SBP from baseline at each time point [ Time Frame: Every 1.5 minutes during the first 30 minutes of clevidipine infusion (approximately 20 measurements) ]
  7. Efficacy: Percent change from baseline in SBP [ Time Frame: At each hour after 30 minutes post-clevidipine infusion through termination of clevidipine infusion (up to a maximum of 96 measurements) ]
  8. Efficacy: Percent change from baseline in SBP over the first 8 hours post-study drug termination [ Time Frame: During the first 8 hours after termination of clevidipine infusion ]
  9. Efficacy: Percent change from baseline in heart rate [ Time Frame: During the first 30 minutes of clevidipine infusion ]
  10. Efficacy: Percent change from baseline in heart rate [ Time Frame: 30 minutes post-clevidipine infusion through termination of clevidipine infusion (minimum of <1 minute up to a maximum of 95 1/2 hours) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Less than 18 years of age
  • Written informed consent obtained before initiation of any study-related procedures
  • The enrolling physician determines that the participant will likely require a 15% reduction in BP during the perioperative course
  • Intra-arterial line is available for blood pressure monitoring
  • Surgical procedure requiring a minimum of 1 hour of anesthesia, in which IV antihypertensive therapy to control BP for at least 30 minutes is anticipated

Exclusion Criteria:

  • Administration of an IV or oral antihypertensive agent within 2 hours prior to study drug administration
  • Congenital heart disease described as single ventricle
  • Evidence of liver failure, severe liver disease, pulmonary disease (e.g. uncontrolled asthma), hyperlipidemia, lipoid nephrosis, lipid dysfunction or acute pancreatitis
  • Allergy to soya bean oil or egg lecithin
  • Known to be intolerant to calcium channel blockers
  • Hemophilia or blood coagulation disorders
  • Any serious medical condition which, in the opinion of the investigator, is likely to interfere with study procedures
  • Clinically significant abnormal physical findings at the screening evaluation
  • Any serious surgical or medical condition which, in the opinion of the investigator, is likely to interfere with study procedures or with the pharmacokinetics or pharmacodynamics of the study drug
  • Participant is terminally ill (death likely to occur within 48 hours)
  • Use of Methylphenidate, calcium channel blockers, Aripiprazole and other atypical anti- psychotics and antihypertensives used for BP control within 2 hours prior to study drug initiation
  • Positive serum or urine pregnancy test for any female of child bearing potential
  • Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of enrollment
  • Participants who, for any reason, are deemed by the Investigator to be inappropriate for this study
  • Participant is a relative of the Investigator or his/her deputy, research assistant, pharmacist, study coordinator, other staff directly involved in the conduct of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01938547


Locations
Layout table for location information
United States, California
Stanford Medical Center
Stanford, California, United States, 94305
United States, Ohio
Nationwide Children's Hospital
Columbus, Ohio, United States, 43205
Sponsors and Collaborators
Chiesi Farmaceutici S.p.A.
Investigators
Layout table for investigator information
Principal Investigator: Joseph D Tobias, MD Nationwide Children's Hospital

Layout table for additonal information
Responsible Party: Chiesi Farmaceutici S.p.A.
ClinicalTrials.gov Identifier: NCT01938547     History of Changes
Other Study ID Numbers: MDCO-CLV-12-01
First Posted: September 10, 2013    Key Record Dates
Last Update Posted: May 15, 2017
Last Verified: May 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Chiesi Farmaceutici S.p.A.:
perioperative
blood pressure
pediatrics
pediatric surgery

Additional relevant MeSH terms:
Layout table for MeSH terms
Clevidipine
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs